Pembrolizumab dose-optimization study with Regression discontinuity design In patients with non-small cell lung Cancer to avert Excessive toxicity and cost (PRICE): Sub-study

The requested reference [d201298a5f11445915ba98e75a2facfe9c52571d] no longer exists in our database. It has been replaced by the current reference: [d655c865cc70e5f3b77d707fe127572e6e51a6d6]

Authors
Category Primary study
Registry of TrialsUMIN Clinical Trials Registry
Year 2026
This article has no abstract
Epistemonikos ID: f11ba110a03f1253a1db4f9e885a1202334bf22d
First added on: Oct 10, 2026